Unknown

Dataset Information

0

SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.


ABSTRACT: SETD2, an epigenetic tumor suppressor, is frequently mutated in MLL-rearranged (MLLr) leukemia and relapsed acute leukemia (AL). To clarify the impact of SETD2 mutations on chemotherapy sensitivity in MLLr leukemia, two loss-of-function (LOF) Setd2-mutant alleles (Setd2F2478L/WT or Setd2Ex6-KO/WT) were generated and introduced, respectively, to the Mll-Af9 knock-in leukemia mouse model. Both alleles cooperated with Mll-Af9 to accelerate leukemia development that resulted in resistance to standard Cytarabine-based chemotherapy. Mechanistically, Setd2-mutant leukemic cells showed downregulated signaling related to cell cycle progression, S, and G2/M checkpoint regulation. Thus, after Cytarabine treatment, Setd2-mutant leukemic cells exit from the S phase and progress to the G2/M phase. Importantly, S and G2/M cell cycle checkpoint inhibition could resensitize the Mll-Af9/Setd2 double-mutant cells to standard chemotherapy by causing DNA replication collapse, mitotic catastrophe, and increased cell death. These findings demonstrate that LOF SETD2 mutations confer chemoresistance on AL to DNA-damaging treatment by S and G2/M checkpoint defects. The combination of S and G2/M checkpoint inhibition with chemotherapy can be explored as a promising therapeutic strategy by exploiting their unique vulnerability and resensitizing chemoresistant AL with SETD2 or SETD2-like epigenetic mutations.

SUBMITTER: Dong Y 

PROVIDER: S-EPMC6785365 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


SETD2, an epigenetic tumor suppressor, is frequently mutated in MLL-rearranged (MLLr) leukemia and relapsed acute leukemia (AL). To clarify the impact of SETD2 mutations on chemotherapy sensitivity in MLLr leukemia, two loss-of-function (LOF) Setd2-mutant alleles (Setd2<sup>F2478L/WT</sup> or Setd2<sup>Ex6-KO/WT</sup>) were generated and introduced, respectively, to the Mll-Af9 knock-in leukemia mouse model. Both alleles cooperated with Mll-Af9 to accelerate leukemia development that resulted in  ...[more]

Similar Datasets

| S-EPMC7659109 | biostudies-literature
| S-EPMC6281863 | biostudies-literature
| S-EPMC6406869 | biostudies-literature
| S-EPMC7118887 | biostudies-literature
| S-EPMC8282743 | biostudies-literature
| S-EPMC8471172 | biostudies-literature
| S-EPMC6949268 | biostudies-literature
| S-EPMC4440318 | biostudies-literature
| S-EPMC5096802 | biostudies-other
| S-EPMC3433102 | biostudies-literature